HLA B Leader in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
• For the Patient group:
• Patient over 18 years of age
• Patient affiliated to a social security scheme
• Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
• For the control group:
• Individuals over 18 years of age
• Individual affiliated to a social security scheme
• Individual having agreed to participate in the study
• Individuals with no inflammatory or autoimmune diseases